474417-42-0

Basic information

• Product Name: Piperazine, 3-methyl-1-(2-pyridinyl)-, (3S)- (9CI)
• Synonyms: Piperazine, 3-methyl-1-(2-pyridinyl)-, (3S)- (9CI);(3S)-3-METHYL-1-PYRIDIN-2-YLPIPERAZINE;(3S)-3-Methyl-1-(2-pyridinyl)-piperazine
• CAS NO: 474417-42-0
• Molecular Formula: C10H15N3
• Molecular Weight: 177.2462
• Product Categories: PIPERIDINE;pharmacetical
• Mol File: 474417-42-0.mol

Chemical Properties

• Boiling Point: 317.6°C at 760 mmHg
• Flash Point: 145.9°C
• Appearance: /
• Density: 1.036g/cm³
• Vapor Pressure: 0.000382mmHg at 25°C
• Refractive Index: 1.527
• CAS DataBase Reference: Piperazine, 3-methyl-1-(2-pyridinyl)-, (3S)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Piperazine, 3-methyl-1-(2-pyridinyl)-, (3S)- (9CI)(474417-42-0)
• EPA Substance Registry System: Piperazine, 3-methyl-1-(2-pyridinyl)-, (3S)- (9CI)(474417-42-0)

Safety Data

• Hazardous Substances Data: 474417-42-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H15N3/c1-9-8-13(7-6-11-9)10-4-2-3-5-12-10/h2-5,9,11H,6-8H2,1H3/t9-/m0/s1

Upstream product

• 109-04-6 2-bromo-pyridine 
• 169447-70-5 (S)-2-methyl-piperazine-1-carboxylic acid tert-butyl ester 
• 1396753-26-6 (S)-tert-butyl 2-methyl-4-(pyridin-2-yl)piperazine-1-carboxylate 
• 74879-18-8 (S)-2-methylpiperazine 

Relevant articles and documents

PHENYL mTORC INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF

The present invention is related to N-hydroxyamide derivatives of Formula (I) and use thereof, in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.

Benzimidazoles that are useful in treating sexual dysfunction

The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction, wherein L is C1-4 alkyl;RA, RB, RC, RD, and RE, are as described in the specification;Z is selected from the group consisting of N, C and CH; andA is aryl and heteroaryl as described in the specification.

Oximes and hydrazones that are useful in treating sexual dysfunction

The present invention relates to oximes and hydrazones of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.

Acetamides and benzamides that are useful in treating sexual dysfunction

The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.

Benzimidazoles that are useful in treating sexual dysfunction

The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.

Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction

A new class of agents with potential utility for the treatment of erectile dysfunction has been discovered, guided by the hypothesis that selective D 4 agonists are erectogenic but devoid of the side effects typically associated with dopaminergic agents. The lead agent 2-(4-pyridin-2-ylpiperazin- 1-ylmethyl)-1H-benzimidazole (1, ABT-724) was discovered by optimization of a series of benzimidazole arylpiperazines. This highly selective D4 agonist was found to be very potent and efficacious in vivo, eliciting penile erections in rats at a dose of 0.03 μmol/kg, with a positive response rate of 77% erectile incidence. Even at high doses, it was devoid of side effects in animal models of central nervous system behaviors, emesis, or nausea. The structure-activity relationship of the parent benzimidazole series leading to 1 is described, with the detailed in vitro and in vivo profiles described. Distinctive structural features were discovered that are associated with D 4 selective agonism in this series of analogues.

Acetamides and benzamides that are useful in treating sexual dysfunction

The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.

Benzimidazoles that are useful in treating sexual dysfunction

The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.